Design Therapeutics, Inc. DSGN EBITDA

EBITDA at other companies

ALN

Alnylam PharmaceuticalsALNY

$245.34M+10,980%

Intellia TherapeuticsNTLA

-$110.66M-2.9%

CRISPR TherapeuticsCRSP

-$125.93M+12.4%

Dyne Therapeutics, Inc.DYN

-$124.73M-2.3%

CytomX TherapeuticsCTMX

-$23.75M-1,801%

Taysha Gene Therapies, Inc.TSHA

-$46.95M-77.5%

FAQ

What is Design Therapeutics, Inc.'s EBITDA?

Design Therapeutics, Inc. (DSGN) reported EBITDA of -$19.55M in Q1 2026.

How has Design Therapeutics, Inc.'s EBITDA changed year-over-year?

Design Therapeutics, Inc.'s EBITDA increased by 3.5% year-over-year, from -$20.26M to -$19.55M.

What is the long-term trend for Design Therapeutics, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s EBITDA has grown at a 21.9% compound annual growth rate (CAGR), from -$35.7M to -$78.85M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.